PESQUISA VETERINÁRIA BRASILEIRA

Abstract in English:

Plasmid-mediated polymyxin resistance was first described in 2015, in China, in Escherichia coli carrying the mcr-1 (Mobile Colistin Resistance-1) gene. Since then, it has become a major public health challenge worldwide, representing a major threat to human and animal health. In addition, there are still few reports on the prevalence of mcr-1 in Enterobacteriaceae isolated from humans, animals and food. Therefore, the purpose of the study was to investigate the occurrence of the mcr-1 gene in bacterial isolates with phenotypic resistance to polymyxin B obtained from clinical specimens of companion animals. Phenotypic resistance to polymyxin B were determined by broth microdilution and the susceptibility profile to other antimicrobials (amikacin, amoxicillin/clavulanate, ampicillin, ampicillin/sulbactam, aztreonam, cefazolin, cefepime, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, chloramphenicol, ciprofloxacin, doxycycline, ertapenem, gentamicin, imipenem, marbofloxacin, meropenem, phosphomycin, piperacillin/tazobactam, tetracycline, ticarcillin/clavulanate, tobramycin and trimethoprim/sulfamethoxazole) by disc-diffusion agar method. The extraction of bacterial DNA was performed via heat shock followed by spectrophotometric evaluation. To verify the presence of mcr-1, the Polymerase Chain Reaction was employed using specific primers, followed by agarose gel electrophoresis. The positive isolates had the corresponding amplicons sequenced. In this study, there were identified the first isolates of Escherichia coli, Klebsiella spp. and Enterobacter spp. carrying the mcr-1 gene derived from specimens of companion animals in Brazil. Our results suggest the dissemination of resistance to polymyxins in the community and the environment, highlighting the need for surveillance and optimized treatment guidelines.

• mcr-1-carrying Enterobacteriaceae companion animals Brazil bacterium polymyxin B multiple drug resistance MDR genes mcr-1 gene

Abstract in Portuguese:

A resistência à polimixina mediada por plasmídeo teve sua primeira descrição em 2015, na China, em Escherichia coli portadora do gene mcr-1 (Mobile Colistin Resistance-1) e a partir de então tornou-se um grande desafio para a saúde pública em todo o mundo, constituindo uma grande ameaça à saúde humana e animal. Além disso, ainda existem poucos relatos sobre a prevalência de mcr-1 em Enterobacteriaceae isoladas de humanos, animais e alimentos. Sendo assim, o objetivo do estudo foi investigar a ocorrência do gene mcr-1 em isolados bacterianos com resistência fenotípica à polimixina B, oriundos de materiais clínicos de animais de companhia. A resistência fenotípica à polimixina B foi determinada por microdiluição em caldo e o perfil de sensibilidade aos demais antimicrobianos (amicacina, amoxicilina/clavulanato, ampicilina, ampicilina/sulbactam, aztreonam, cefazolina, cefepime, cefotaxima, cefoxitina, ceftazidima, ceftriaxona, cloranfenicol, ciprofloxacina, doxiciclina, ertapenem, gentamicina, imipinem, marbofloxacino, meropenem, fosfomicina, piperacilina/tazobactam, tetraciclina, ticarcilina/clavulanato, tobramicina sulfametoxazol/trimetoprim) foram determinados pelo método disco difusão. A extração do DNA bacteriano foi realizada via choque térmico, seguido de avaliação espectrofotométrica. Para a verificação da presença do mcr-1 foi utilizada a Reação em Cadeia da Polimerase com emprego de iniciadores específicos, seguida de eletroforese em gel de agarose. Os isolados positivos tiveram os correspondentes amplicons sequenciados. Nesse estudo foram identificados os primeiros isolados de Escherichia coli, Klebsiella spp. e Enterobacter spp. portadores do gene mcr-1 derivados de espécimes de animais de companhia no Brasil. Este estudo sugere a disseminação da resistência às polimixinas na comunidade e no meio ambiente, destacando a necessidade de vigilância e diretrizes otimizadas de tratamento.

• Enterobacteriaceae portadora de mcr-1 animais de companhia Brasil bactérias polimixina B resistência a múltiplos medicamentos genes MDR gene mcr-1

Abstract in English:

ABSTRACT.- Medeiros F.P., Freitas D.A. & Canola J.C. 2013. [Diffuse echogenicity variation in homogeneous liver parenchyma related to biochemical and hematological findings in dogs.] Variação da ecogenicidade difusa em parênquima hepático homogêneo relacionada aos achados bioquímicos e hematológicos em cães. Pesquisa Veterinária Brasileira 33(Supl.1):85-92. Departamento de Cirurgia Veterinária, Faculdade de Ciências Agrárias e Veterinárias, Universidade Estadual Paulista Júlio de Mesquita Filho, Campus de Jaboticabal, SP 14884-900, Brazil. E-mail: femedeiros_vet@yahoo.com.br The present study evaluated the liver with homogeneous parenchyma in dogs, with diffuse reduced echogenicity (G1), increased echogenicity (G2) and normal echogenicity (G3) by ultrasound examination associating the findings on animal profile, liver size and hematology and biochemistry results. Blood samples obtained by cephalic or jugular venipunture were submitted for hemogram and ALT, ALP, total proteins, albumin, globulin, urea and creatinine analysis. Among the 30 dogs in G1, 30 (100%) presented portal venous and gall bladder wall clarity, 23 (76.67%) presented normal liver size and edges, 15 (50%) were from 1 to 6 years old and 8 (26.67%) belonged to the lhasa apso breed. No predispositions were found according to gender, as well as no significant alterations in biochemical and hematological exams were observed in G1. The most prevalent disease found in this group was gastroenteritis (43.33%). Among the 30 dogs in G2, 27 (90%) presented hepatomegaly and rounded hepatic edges, 18 (60%) were over 9 years old, 16 (53.33%) were female and 9 (30%) belonged to the poodle breed. The laboratorial findings related to this group were increased ALT and ALP serum activity, decreased levels of total protein, albumin, globulin, erythrocytes and hematocrit, as well as leukocytosis with neutrophilia and a left shift, eosinopenia, lymphopenia and monocytosis. The most prevalent diseases found in this group were metabolic disorders (54%), such as diabetes mellitus and hyperadrenocorticism, and chronic hepatopathies (17%) due to prolonged and continuous use of corticoid and anticonvulsive drugs. Among the 30 dogs in the control group (G3), normal liver size and edges were presented in 22 (73.33%). In this group, no alterations were seen in laboratorial exams.

• Liver hematology fígado hematologia

Abstract in Portuguese:

RESUMO.- Medeiros F.P., Freitas D.A. & Canola J.C. 2013. [Diffuse echogenicity variation in homogeneous liver parenchyma related to biochemical and hematological findings in dogs.] Variação da ecogenicidade difusa em parênquima hepático homogêneo relacionada aos achados bioquímicos e hematológicos em cães. Pesquisa Veterinária Brasileira 33(Supl.1):85-92. Departamento de Cirurgia Veterinária, Faculdade de Ciências Agrárias e Veterinárias, Universidade Estadual Paulista Júlio de Mesquita Filho, Campus de Jaboticabal, SP 14884-900, Brazil. E-mail: femedeiros_vet@yahoo.com.br No presente estudo foi analisado o parênquima hepático com características homogêneas e ecogenicidade difusa reduzida (G1), aumentada (G2) e normal (G3), em relação ao perfil dos animais, dimensão do fígado e achado bioquímico e hematológico. Amostras de sangue obtidas por punção venosa da jugular ou da cefálica do antebraço foram encaminhadas para realização de hemograma e dosagem sérica de ALT, FA, proteínas totais, albumina, globulina, uréia e creatinina. Dos 30 cães que compuseram o G1, 30 (100%) apresentaram evidenciação das paredes portais e da parede da vesícula biliar, 23 (76,67%) fígado com dimensão preservada e bordos em ângulos agudos, 15 (50%) faixa etária entre 1 e 6 anos de idade e 8 (26,67%) eram da raça Lhasa apso. Não houve predisposição quanto ao sexo, assim como não foram identificadas alterações significativas nos exames bioquímicos e hematológicos dos cães do G1. Quanto aos diagnósticos clínicos atribuídos para estes cães, houve maior prevalência de gastroenterite (43,33%). Dos 30 cães do G2, 27 animais (90%) apresentaram hepatomegalia e arredondamento dos bordos hepáticos, 18 (60%) tinham idade superior a 9 anos, 16 (53,33%) eram fêmeas e 9 (30%) eram da raça poodle. Houve elevação da atividade sérica de FA e elevação de ALT, redução nos níveis de proteínas séricas totais, albumina, globulinas, eritrócitos e volume globular, além de leucocitose por neutrofilia, com desvio à esquerda, eosinopenia, linfopenia e monocitose nos cães do G2. Neste grupo houve prevalência de doenças metabólicas (54%), como diabetes mellitus e hiperadrenocorticismo, além das hepatopatias crônicas (17%), atribuídas ao uso contínuo e prolongado de corticóide e drogas anticonvulsivantes. Dos 30 cães do grupo controle (G3), 22 (73,33%) apresentaram dimensões hepáticas inalteradas e bordos em ângulos agudos. Neste grupo de animais, não houve alterações significativas nos exames laboratoriais.

Abstract in English:

ABSTRACT.- Lima E.Q., Albuquerque M.M., Rodrigues O.G., Alencar J.R.B., Medeiros F.P.M. & Neto P.R. 2007. Technological development of (40mg) furosemide tablets: a equivalence and bioavaibility study in dogs. Pesquisa Veterinária Brasileira 27(11):462.466. Unidade Acadêmica de Medicina Veterinária (UAMV), Centro de Saúde e Tecnologia Rural (CSTR), Universidade Federal de Campina Grande (UFCG), Av. Acadêmica s/n, Santa Cecília, Cx. Postal 64, Patos, PB 58708110, Brazil. E-mail: onaldo@cstr.ufcg.edu.br Furosemide (40mg) was administered to 20 street dogs, 10 males and 10 females, in two different pharmaceutical forms: (1) compressed furosemide 40mg formulated at the Federal University of Pernambuco (UFPE-tablet), and (2) a commercial formulation with equal bioequivalence produced by the Laboratory for Pharmaceutical Technology of Pernambuco State (LAFEPE), the LAFEPE-furosemide. The study aimed to evaluate the kinetics of dissolution of the UFPE-tablet in order to analyze the behavior of bioavailability of the best formulation for veterinary use. The plasmatic concentrations of furosemide for the determination of parameters of pharmacological kinetics were analyzed by high-performance liquid chromato-graphic method (HPLC). The in vitro study accomplished through physiochemical analyses demonstrated that the formulas of the furosemide tablets attained the pharmaceutical requirements in agreement with USP 23 and the Brazilian Pharmacopoeia. The evaluation accomplished in dogs with UFPE-tablets given in only dose demonstrated uniformity in blood levels indicating stability in maintenance of the pharmaceutical formulation and efficiency in absorption of the active compound. These values are not significantly different in relation to the 5% confidence limit. Regarding maximum concentration (Tmax) time and global bioavaibility assessed by AUC means, there were no considerable differences as well. UFPE-furosemide displayed 743.492µg/mL.h as AUC average value whereas LAFEPE-furosemide had an average of 537.284µg/mL.h.

• Furosemide bioavaibility lyoavailability dogs

Abstract in Portuguese:

ABSTRACT.- Lima E.Q., Albuquerque M.M., Rodrigues O.G., Alencar J.R.B., Medeiros F.P.M. & Neto P.R. 2007. Technological development of (40mg) furosemide tablets: a equivalence and bioavaibility study in dogs. Pesquisa Veterinária Brasileira 27(11):462.466. Unidade Acadêmica de Medicina Veterinária (UAMV), Centro de Saúde e Tecnologia Rural (CSTR), Universidade Federal de Campina Grande (UFCG), Av. Acadêmica s/n, Santa Cecília, Cx. Postal 64, Patos, PB 58708110, Brazil. E-mail: onaldo@cstr.ufcg.edu.br Furosemide (40mg) was administered to 20 street dogs, 10 males and 10 females, in two different pharmaceutical forms: (1) compressed furosemide 40mg formulated at the Federal University of Pernambuco (UFPE-tablet), and (2) a commercial formulation with equal bioequivalence produced by the Laboratory for Pharmaceutical Technology of Pernambuco State (LAFEPE), the LAFEPE-furosemide. The study aimed to evaluate the kinetics of dissolution of the UFPE-tablet in order to analyze the behavior of bioavailability of the best formulation for veterinary use. The plasmatic concentrations of furosemide for the determination of parameters of pharmacological kinetics were analyzed by high-performance liquid chromato-graphic method (HPLC). The in vitro study accomplished through physiochemical analyses demonstrated that the formulas of the furosemide tablets attained the pharmaceutical requirements in agreement with USP 23 and the Brazilian Pharmacopoeia. The evaluation accomplished in dogs with UFPE-tablets given in only dose demonstrated uniformity in blood levels indicating stability in maintenance of the pharmaceutical formulation and efficiency in absorption of the active compound. These values are not significantly different in relation to the 5% confidence limit. Regarding maximum concentration (Tmax) time and global bioavaibility assessed by AUC means, there were no considerable differences as well. UFPE-furosemide displayed 743.492µg/mL.h as AUC average value whereas LAFEPE-furosemide had an average of 537.284µg/mL.h.